AFC
EWTX icon

Ares Financial Consulting’s Edgewise Therapeutics EWTX Stock Holding History

Ares Financial Consulting’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$934 Buy
+23
New +$793 ﹤0.01% 1016

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ares Financial Consulting's EWTX Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 23 shares worth $934. The stake represents ﹤0.01% of the portfolio and ranks #1016 among its holdings.

226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Ares Financial Consulting held 23 shares of Edgewise Therapeutics worth $934 as of Q2 2026.
  • Edgewise Therapeutics was a new Ares Financial Consulting position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1016 holding.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.